Evolution of Diabetes Technology.
Blood Glucose Self-Monitoring
/ instrumentation
Decision Support Systems, Clinical
/ instrumentation
Diabetes Mellitus, Type 1
/ blood
Equipment and Supplies
Humans
Injections, Subcutaneous
/ instrumentation
Insulin
/ administration & dosage
Insulin Infusion Systems
/ trends
Inventions
/ trends
Pancreas, Artificial
/ trends
Artificial pancreas
Closed loop
Continuous glucose monitoring
Insulin pump
Multiple daily injections
Self-monitoring of blood glucose
Technology
Type 1 diabetes
Journal
Endocrinology and metabolism clinics of North America
ISSN: 1558-4410
Titre abrégé: Endocrinol Metab Clin North Am
Pays: United States
ID NLM: 8800104
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
entrez:
26
1
2020
pubmed:
26
1
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Technological innovations have fundamentally changed diabetes care. Insulin pump use and continuous glucose monitoring are associated with improved glycemic control along with a better quality of life; automated insulin-dosing advisors facilitate and improve decision making. Glucose-responsive automated insulin delivery enables the highest targets for time in range, lowest rate and duration of hypoglycemia, and favorable quality of life. Clear targets for time in ranges and a standard visualization of the data will help the diabetes technology to be used more efficiently. Decision support systems within and integrated cloud environment will further simplify, unify, and improve modern routine diabetes care.
Identifiants
pubmed: 31980111
pii: S0889-8529(19)30091-X
doi: 10.1016/j.ecl.2019.10.009
pii:
doi:
Substances chimiques
Insulin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-18Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure T. Battelino served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic, and Bayer HealthCare. T. Battelino’s institution received research grant support, with receipt of travel and accommodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz, and Diamyd. K. Dovc declares that there is no duality of interest associated with his contribution to this article.